Cost-effectiveness of treatments in psoriasis

Journal of Dermatological Treatment

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Lambert, J R M G ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Costs; Economic evaluation; Effectiveness; Pharmacoeconomics; Psoriasis

Indexed keywords

CALCIPOTRIOL; CYCLOSPORIN; ETRETINATE; HYDROXYUREA; METHOTREXATE;

CHRONIC DISEASE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; DECISION MAKING; ECONOMIC EVALUATION; EUROPE; HEALTH CARE FINANCING; HUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSYCHOSOCIAL DISORDER; PUVA; QUALITY OF LIFE; RESOURCE MANAGEMENT;

EID: 0033018151     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Annuaires Demographiques 1993. United Nations: New York, 1995.
2. Sander HM, Morris LF, Phillips CM et al, The annual cost of psoriasis. J Am Acad Dermatol (1993) 28: 422-5.
3. Drummond MF, Stoddart GL, Torrance GW, Methods for the economic evaluation of health care programs. Oxford University Press: Oxford, 1987, p 8.
4. Freund DA, Dittus RS, Principles of pharmaco-economic analysis of drug therapy. Pharmacoeconomics (1992) 1:20-32.
5. Ellis NC, Hermann RC, Gorsulowsky DC et al, Etretinate therapy reduces inpatient treatment of psoriasis. J Am Acad Dermatol (1987) 17: 787-91.
6. Cork M, Economic considerations in the treatment of psoriasis. Dermatol Practice (1993) 1: 16-20.
7. Einarson TR, Arikian PR, Shear N, Oral treatments for severe psoriasis: government payor analysis for Canada. J Dermatol Treat (1994) 5(Suppl 1): S23-7.
8. Snellman E, Maljanen T, Aromaa A et al, Effect of heliotherapy on the cost of psoriasis. Br J Dermatol (1998) 138: 288-92.
9. Davies L, Levell N, Munro CS et al, Short course cyclosporin therapy for psoriasis: benefits, risks and costs. Br J Dermatol (1997) 137(Suppl 50): 53.
10. Boffa MJ, Chalmers RJG, Haboubi NA et al, Sequential liver biopsies during long-term methotrexate for psoriasis: a reappraisal. Br J Dermatol (1995) 133: 774-8.
11. Roenigk HH, Auerbach R, Maibach H et al, Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 38: 478-85.
12. Powles AV, Hardman CM, Porter WM et al, Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol (1998) 138: 443-9.
13. Zachariae H, Kragballe K, Hansen HE et al, Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol (1997) 136: 531-5.
14. Grossman RM, Chevret S, Abi-Rached J et al, Long-term safety of cyclosporin in the treatment of psoriasis. Arch Dermatol (1996) 132: 623-9.
15. Zachariae H, Long-term use of cyclosporin in dermatology. Arch Dermatol (1996) 132: 692-4.
16. Kaplan NM, Pitfalls in the interpretation of pharmacoeconomic studies. Pharmacoeconomics (1992) 1: 303-5.